Recently, I was approached by a colleague who had seen a patient with type 1 diabetes using a glucagon-like peptide-1 receptor agonist in combination with basal bolus insulin to manage their glucose levels.
A study of 46,000 adults quantifies the impact of the disease according to its severity. This finding also holds true for people who have never smoked.
Treatments like corticosteroid and platelet-rich plasma injections have been touted as offering fast relief for lateral epicondylitis, but fresh evidence suggests it might be time for a different game plan.